AKI Clinical Trial
Official title:
Association of Preadmission Metformin Exposure and Incidence of Acute Kidney Injury Within 7 Days in Patients With Type 2 Diabetes in Intensive Care Unit: a Retrospective Cohort Study
More than 50% of ICU patients suffer from Acute kidney injury (AKI). Metformin shows protective properties in kidney disease. Our study aimed to validate AKI incidence among diabetes patients in the ICU with or without preadmission metformin exposure. We included non-AKI patients with type 2 diabetes in Medical Information Mart for Intensive Care (MIMIC)-III database. Incidence of AKI and mortality were compared between those with and without preadmission prescriptions.
Emerged as a major public healthy problem, Acute kidney injury (AKI) is now influencing millions of people worldwide and leading to reduced survival, increased progression of latent chronic kidney disease (CKD), and even new onset of CKD. More than half of intensive care unit (ICU) patients underwent AKI in a recent multinational cross-sectional study, often resulting in the need for renal replacement therapy with a high socio-economic impact for the patients.The effective precaution and treatment strategy remains limited. As the most general and first-line biguanide antihyperglycemic drug, metformin has anti-inflammatory characteristics and is related with decreased all-cause mortality compared with other antihyperglycemics.. In some clinical trials and experimental studies conducted on divergent rodent models representing various types of kidney diseases going from AKI to CKD, metformin has been shown beneficial effects on the kidney. Moreover, preadmission metformin exposure is associated with a lower rate of 28-day mortality among AKI patients showed in several clinical studies. However, in critical care patients with type 2 diabetes, the evidence of preadmission metformin usage decreasing a risk of AKI incidence is still absented. Therefore we performed a retrospective cohort study to validate the association of preadmission metformin exposure and AKI incidence in patients with diabetes in the ICU . ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04112953 -
Intraoperative Transesophageal Echocardiography Assessment of Portal Vein Flow and Renal Resistive Index As a Predictor of Acute Kidney Injury After Cardiac Surgery: A Prospective Observational Study
|
||
Completed |
NCT04395911 -
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
|
N/A | |
Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
Active, not recruiting |
NCT04008810 -
Serum Neutrophil Gelatinase-associated Lipocalins (NGAL) and Chronic Kidney Disease
|
||
Recruiting |
NCT04597034 -
Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) vs (Standard AN-69) in COVID-19
|
N/A | |
Completed |
NCT04458571 -
Effect of CRRT Duration on Solute Removal
|
||
Recruiting |
NCT04114747 -
Renal Physiology During Continuous Renal Replacement Therapy
|
N/A | |
Completed |
NCT05094154 -
Effect of Antibiotic Choice On ReNal Outcomes (ACORN)
|
Phase 4 | |
Enrolling by invitation |
NCT04491227 -
Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection
|
||
Not yet recruiting |
NCT05382078 -
Nafamostat Mesilate for Anticoagulation During CRRT in Critically Ill Patients
|
||
Recruiting |
NCT04351906 -
Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome
|
N/A | |
Recruiting |
NCT06416761 -
Genetics in the Progression of Nephropathies
|
||
Completed |
NCT04762524 -
The Impact of CRRT Modality on Filter Life
|
N/A | |
Completed |
NCT04048525 -
Cytokine Removal With CVVHD Compared to CVVH
|
N/A | |
Completed |
NCT04788394 -
Renal Involvement in Hospitalized Children With COVID-19
|
||
Recruiting |
NCT04474249 -
Follow-up of Critical COVID-19 Patients
|
||
Completed |
NCT04407156 -
Epidemiology of Acute Kidney Injury in COVID19 Disease in United Kingdom
|
||
Completed |
NCT04517630 -
Renal Biomarkers in AKI and COVID-19
|
||
Recruiting |
NCT04895384 -
El DORADO STUDY (Evaluation of Delivery of Oxygen on Renal, Arrhythmia and Delirium Outcomes Study)
|
||
Completed |
NCT03070353 -
Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury
|
Phase 2/Phase 3 |